ClinicalTrials.gg
Not yet recruitingNCT07830940Updated Sep 22, 2026

Finerenone and Cardiac Remodeling in HFpEF

A Phase 4 interventional study of Finerenone and Standard of care for HFpEF Description: in Heart Failure With Preserved Ejection Fraction, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by Assiut University · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
194
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing finerenone in Heart Failure — 16 open to participants now, 17 under way, 8 of them phase 3. finerenone · Heart Failure.

Planned enrollment
10th of 23
194 · median 120
Started
2026
with 9 others
Phase 4
6 of 23
5 open now
Primary completion
2027-09
later than 5 of 16 live
Registered
23rd of 23
by date
Lead sponsor
1 of 23
Assiut University

Among the 23 studies testing finerenone in Heart Failure, this one is the 10th largest by planned enrollment, is one of 10 that started in 2026, is one of 6 in phase 4, reaches primary completion later than 5 of the 16 other live ones, and was the 23rd registered.

Heart Failure

6,332 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.

Browse Heart Failure studies →

Open to participants now

16 of the 23 studies testing finerenone in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About finerenone

finerenone: first FDA approval 2021 (KERENDIA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing finerenone in Heart Failure, or all of them as a file.
02

Study summary

This prospective randomized study aims to evaluate the efficacy of Finerenone as add-on therapy to standard of care compared to standard of care alone in preventing heart failure worsening and preserving cardiac function assessed by left ventricular strain in patients with heart failure with preserved ejection fraction.

Read the detailed description

Overactivation of the mineralocorticoid receptor drives inflammation fibrosis and heart failure progression. Left ventricular global longitudinal strain measured by speckle tracking echocardiography is a sensitive marker for early myocardial remodeling. This is a prospective randomized parallel assignment study. Patients with HFpEF defined by HFA-PEFF score will be randomized to Finerenone plus standard of care or standard of care alone and followed for 6 months with clinical laboratory ECG and echocardiography assessment including speckle tracking at baseline and 6 months.

03

Conditions studied

  • Heart Failure With Preserved Ejection Fraction

Browse trials for

Keywords

  • Cardiac remodeling
  • Finerenone
  • HFpEF
  • Global longitudinal strain
  • Speckle tracking
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age greater than or equal to 18 years
  • Clinically evidenced heart failure with greater than or equal to 50 percent
  • HFA-PEFF score greater than or equal to 5 or score 2 to 4 with functional testing confirming HFpEF
  • Sinus rhythm on resting at screening
  • Written

Exclusion criteria

Exclusion Criteria:

  • Implanted cardiac pacemaker or defibrillator with active atrial pacing
  • Estimated less than 25 milliliters per minute per 1.73 square meters
  • Baseline serum potassium greater than 5 milliequivalents per liter
  • Known to Finerenone
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
194 participants (estimated)

Study arms

  • Experimental
    Finerenone plus Standard of Care

    Finerenone 10 mg once daily titrated to 20 mg once daily based on serum potassium and eGFR plus standard of care for HFpEF for 6 months

    Drug: Finerenone · Other: Standard of care for HFpEF Description:

  • Active comparator
    Standard of Care alone

    Standard of care for HFpEF according to 2022 AHA ACC HFSA guideline without Finerenone

    Other: Standard of care for HFpEF Description:

Interventions

  • Non-steroidal mineralocorticoid receptor antagonist 10 to 20 mg orally once daily for 6 months with monitoring of potassium creatinine and eGFR

  • OtherStandard of care for HFpEF Description:

    Standard of care for heart failure with preserved ejection fraction according to 2022 AHA ACC HFSA guideline including diuretics and guideline-directed medical therapy without Finerenone

06

What researchers measure

Primary outcomes

  1. Change in left ventricular global longitudinal strain

    Absolute change in left ventricular global longitudinal strain measured by speckle tracking echocardiography using QLAB 10.4 software from apical four-chamber views with three consecutive heart cycles greater than 61 frames per second. More negative values indicate better function

    Time frame: From baseline to 6 months

Secondary outcomes

  1. Change in left ventricular reservoir strain

    Absolute change in left ventricular reservoir strain measured by speckle tracking echocardiography from baseline to 6 months

    Time frame: From baseline to 6 months

  2. Number of participants with heart failure hospitalization

    Number of participants who experience heart failure hospitalization

    Time frame: Up to 6 months

  3. Number of participants with major adverse cardiovascular events

    Number of participants with non-fatal myocardial infarction or ischemic stroke

    Time frame: Up to 6 months

  4. Change in NT-proBNP level

    Change in N-terminal pro B-type natriuretic peptide level in picograms per milliliter

    Time frame: From baseline to 6 months

  5. Change in NYHA functional class

    Change in New York Heart Association functional class score range 1 to 4 with higher scores indicating worse symptoms

    Time frame: From baseline to 6 months

  6. Number of participants with dyspnea worsening

    Number of participants with worsening of dyspnea assessed by five-point Likert scale score range 1 to 5 with higher scores indicating worse dyspnea

    Time frame: Up to 6 months

  7. Number of participants with diuretic dose escalation

    Number of participants who require diuretic dose escalation during the 6-month follow-up

    Time frame: Up to 6 months

  8. Number of participants with hyperkalemia

    Number of participants who develop hyperkalemia defined as serum potassium greater than 5.5 milliequivalents per liter

    Time frame: Up to 6 months

  9. Number of participants with acute kidney injury

    Number of participants who develop acute kidney injury defined as increase in serum creatinine greater than 0.3 milligrams per deciliter

    Time frame: Up to 6 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.

Of 164 non-industry phase 4 interventional studies under Heart Failure, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 12 months is below that.

Counting every sponsor, half of 183 studies reached it within 31 months; a quarter within 22 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2026
First posted
Sep 21, 2026
StartEst.
Sep 20, 2026
Primary completionEst.
Sep 25, 2027
CompletionEst.
Mar 25, 2028
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07830940
Lead sponsor
Assiut University
Responsible party
Mostafa Mohamed Khairy (Resident Physician, Department of cardiovascular, Assiut University) — Principal investigator
First posted
Sep 21, 2026
Start date
Sep 20, 2026 (estimated)
Primary completion
Sep 25, 2027 (estimated)
Completion
Mar 25, 2028 (estimated)
Last update
Sep 22, 2026

Study contacts

Mostafa M Khairy, Resident
Contact
Mostfa.elfraa@gmail.com
01145340851
Ahmed A Ahmed, prof
study chair · Cardiovascular Medicine Department, Assiut University Hospitals

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Finerenone

Start the discussion